Pediatric neuroenhancement: ethical, legal, social, and neurodevelopmental implications.
about
Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003-2011Chronic methylphenidate treatment during early life is associated with greater ethanol intake in socially isolated rats.Globalization and cognitive enhancement: emerging social and ethical challenges for ADHD clinicians.Attitudes towards prescribing cognitive enhancers among primary care physicians in Germany.Student-Perceived School Climate Is Associated With ADHD Medication Treatment Among Adolescents in Medicaid.Transcranial Electrical Stimulation to Enhance Cognitive Performance of Healthy Minors: A Complex Governance ChallengeAddressing the problem of ADHD medication as neuroenhancements.Unauthorized drug use in the US Army based on medical review officer evaluations.Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?Enhancement for well-being is still ethically challenging.From 'Hard' Neuro-Tools to 'Soft' Neuro-Toys? Refocussing the Neuro-Enhancement Debate.Adderall for All: A Defense of Pediatric Neuroenhancement.Does collateral retrospective information about childhood attention-deficit/hyperactivity disorder symptoms assist in the diagnosis of attention-deficit/hyperactivity disorder in adults? Findings from a large clinical sample.Neuro-Enhancement Practices across the Lifecourse: Exploring the Roles of Relationality and IndividualismAutonomy—A Genuinely Gradual Phenomenon
P2860
Q28304087-82676D66-7C79-4371-B79C-0262CF63535DQ34093252-41A460A5-4872-4F25-A70B-E84776359D2FQ34655248-CDD05B47-E5F5-4EB2-B7A0-19342E9900BDQ35084473-348D5099-0D37-4E77-B650-3ECCBA40FF6DQ35984361-25A6D32C-517B-4DB7-8815-A83F5915AD4CQ37721206-0F1E444D-FCCD-4A62-86FC-1D0E128CFD37Q38205021-78FD09CB-E66C-4297-8F2B-B2994ABFF913Q38227150-91E70BC3-DFD3-4492-B9F5-EAD1B5604D38Q38242438-93100880-695B-4595-8C6E-D987AE76A46DQ39307820-AFF72F9E-646B-4CCC-A925-F62716375A31Q41504468-1529DAE9-40C3-4570-8478-CDE46E40FBD2Q46122028-46CBA661-439F-4EB0-9496-0E15A7985A30Q50560049-C4D5CC36-1B02-4196-A72C-335D9690C5CEQ57563587-E373EBB5-6DDC-478A-9AEF-0C2F877912F0Q58140678-55B2A317-5155-4690-BF38-3356810901BF
P2860
Pediatric neuroenhancement: ethical, legal, social, and neurodevelopmental implications.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pediatric neuroenhancement: ethical, legal, social, and neurodevelopmental implications.
@en
type
label
Pediatric neuroenhancement: ethical, legal, social, and neurodevelopmental implications.
@en
prefLabel
Pediatric neuroenhancement: ethical, legal, social, and neurodevelopmental implications.
@en
P2093
P1433
P1476
Pediatric neuroenhancement: ethical, legal, social, and neurodevelopmental implications.
@en
P2093
Dan Larriviere
Geoffrey Miller
Leon G Epstein
Saskia K Nagel
William D Graf
P304
P356
10.1212/WNL.0B013E318289703B
P407
P577
2013-03-13T00:00:00Z